To date, no RB1 related therapies are currently under investigation for NSCLC, but RB1 been shown as a negative prognostic factor when co-occurring with both TP53 and EGFR mutation and is significantly more susceptible to histological transformation to small cell lung cancer [99]. The gene discussed is RB1; the disease is small cell lung carcinoma.